Crossmark

Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report

Crossref DOI link: https://doi.org/10.1186/s13256-023-04139-x

Published Online: 2023-09-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

del Giglio, Auro

da Costa Aguiar Alves, Beatriz

Murad, André Márcio

Fonseca, Fernando Luiz Affonso
License Information

Text and Data Mining valid from 2023-09-25

Version of Record valid from 2023-09-25
More Information

Article History

Received: 26 June 2023

Accepted: 22 August 2023

First Online: 25 September 2023

Declarations

:

: Not applicable.

: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below